• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

俄罗斯企业信息可获取性与商业透明度的数据。

Data on accessibility of corporate information and business transparency in Russia.

作者信息

Kuzmin Evgeny A, Guseva Valentina E, Fomina Alena V

机构信息

Institute of Economics of the Ural Branch of the Russian Academy of Sciences, Ekaterinburg, Russian Federation.

Ural State University of Economics, Ekaterinburg, Russian Federation.

出版信息

Data Brief. 2018 Sep 21;20:1890-1900. doi: 10.1016/j.dib.2018.09.048. eCollection 2018 Oct.

DOI:10.1016/j.dib.2018.09.048
PMID:30294640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6168793/
Abstract

Empirically based, the data description covers business transparency in Russia and availability of corporate information for interested parties. Entry barriers in the form of a fee for hard copies of documents are perceptible as an important indicator of business publicity. The study made it possible to summarize current data on 5070 Russian enterprises in order to estimate document copying cost differentiation according to the developed model. The sample size made it also possible to ensure high levels of data quality and representativeness. Actual limiting average mean error Δp was 3.47% with 99% of study validity. The analysis relied on regional and sectorial data groupings to show a strength of various impact factors. In view of this, correlation coefficients, average and weighted average cost values, and descriptive statistics became secondary indicators. The cost value distributed along an interval scale is a major empirical result of the research. The examination of the obtained data makes it possible to identify an availability level of corporate information for various stakeholders and the general public. This is a part of civil right enforcement in the field of information control and validity check. Conjugated scientific issues include pricing of non-core services of companies, corporate relations and modelling of market behaviours. By making a representative data set, authors make an effort to fill the fact-based gap available in other disciplines and related to business transparency in Russia.

摘要

基于实证,数据描述涵盖了俄罗斯的商业透明度以及相关方获取公司信息的情况。以文件纸质副本收费形式存在的进入壁垒,可被视为商业公开性的一个重要指标。该研究得以汇总5070家俄罗斯企业的当前数据,以便根据所开发的模型估算文件复印成本差异。样本规模还使得确保高水平的数据质量和代表性成为可能。实际极限平均误差Δp为3.47%,研究有效性为99%。分析依赖于区域和部门数据分组,以显示各种影响因素的强度。有鉴于此,相关系数、平均成本值和加权平均成本值以及描述性统计数据成为次要指标。沿区间尺度分布的成本值是该研究的主要实证结果。对所得数据的审查使得能够确定各类利益相关者和公众获取公司信息的水平。这是信息控制和有效性核查领域民权执法的一部分。相关的科学问题包括公司非核心服务的定价、公司关系以及市场行为建模。通过制作一个具有代表性的数据集,作者努力填补其他学科中存在的、与俄罗斯商业透明度相关的基于事实的空白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5039/6168793/a446918cc7d4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5039/6168793/673639e135e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5039/6168793/a446918cc7d4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5039/6168793/673639e135e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5039/6168793/a446918cc7d4/gr2.jpg

相似文献

1
Data on accessibility of corporate information and business transparency in Russia.俄罗斯企业信息可获取性与商业透明度的数据。
Data Brief. 2018 Sep 21;20:1890-1900. doi: 10.1016/j.dib.2018.09.048. eCollection 2018 Oct.
2
Data on empirically estimated corporate survival rate in Russia.俄罗斯企业经验估计存活率的数据。
Data Brief. 2017 Dec 16;16:850-864. doi: 10.1016/j.dib.2017.12.011. eCollection 2018 Feb.
3
[Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].[跨国研发制药公司的企业社会责任活动与欧洲、日本和美国患者组织之间关系的透明度]
Nihon Koshu Eisei Zasshi. 2019;66(12):746-755. doi: 10.11236/jph.66.12_746.
4
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
5
The impact of transparency constraints on the efficiency of the Russian healthcare system: systematic literature review.透明度限制对俄罗斯医疗体系效率的影响:系统文献综述
J Med Econ. 2023 Jan-Dec;26(1):95-109. doi: 10.1080/13696998.2022.2160608.
6
Understanding and improving the language of business: How accounting and corporate reporting research can better serve business and society.理解并改进商业语言:会计与公司报告研究如何能更好地服务于商业和社会。
J Bus Econ. 2023 May 20:1-36. doi: 10.1007/s11573-023-01158-4.
7
Fighting trafficking of falsified and substandard medicinal products in Russia.打击俄罗斯假药和劣药的非法交易。
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.
8
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
9
Business Ethics 101 for the biotech industry.生物技术行业的商业伦理基础课程。
BioDrugs. 2004;18(2):71-7. doi: 10.2165/00063030-200418020-00001.
10
The business of demographics.人口统计学的事务。
Popul Bull. 1984 Jun;39(3):1-40.